Close Menu

Marina

Restarting the trial will require the company to raise additional funds before its money runs out this summer.

The project stems from a microRNA drug and diagnostics partnership forged earlier this year.

The higher losses came amid increased costs.

Title: Methods and Means for Producing Efficient Silencing Construct Using Recombinatorial Cloning
Patent Number: 8,877,435

NEW YORK (GenomeWeb) – Marina Biotech this week took another step toward reestablishing itself as a player in the nucleic acids drug sector, regaining compliance with US Securities and Exchange Commission financial reporting requirements with the submission of the requisite information for 2012,

Marina Biotech announced that it has appointed Daniel Geffken as its interim CFO as it works to restart drug-development operations after halting operations in mid-2012 amid a cash shortfall. Geffken is managing director at Danforth Advisors.

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Rosetta Genomics and RNA drug developer Marina Biotech today announced that they have forged a microRNA diagnostics and drug discovery and development alliance, focusing on neuromuscular diseases and dystrophies.

Having just closed its first financing transaction in two years, struggling Marina Biotech announced that it plans to continue looking beyond just RNAi and develop drugs using a number of different nucleic acid modalities.

Amid a resurgence of investor interest in RNAi as a therapeutic modality, two of the field's smaller players this week announced financing arrangements expected to help them reach key inflection points — news that prompted double-digit jumps in each company's share price.

Art Krieg has been named as CSO of RNA drug developer Sarepta Therapeutics.

Pages

Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.

Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.

Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.

In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.